A new trading day began on Friday, with Acrivon Therapeutics Inc (NASDAQ: ACRV) stock price up 4.55% from the previous day of trading, before settling in for the closing price of $1.10. ACRV’s price has ranged from $1.09 to $10.16 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 5.79%. With a float of $21.75 million, this company’s outstanding shares have now reached $31.35 million.
Let’s determine the extent of company efficiency that accounts for 78 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Acrivon Therapeutics Inc (ACRV) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Acrivon Therapeutics Inc is 30.62%, while institutional ownership is 56.74%. The most recent insider transaction that took place on Apr 30 ’25, was worth 617,412. In this transaction 10% Owner of this company sold 437,881 shares at a rate of $1.41, taking the stock ownership to the 3,403,025 shares. Before that another transaction happened on May 01 ’25, when Company’s 10% Owner sold 298,886 for $1.34, making the entire transaction worth $400,507. This insider now owns 3,104,139 shares in total.
Acrivon Therapeutics Inc (ACRV) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 5.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.64% during the next five years compared to -74.96% drop over the previous five years of trading.
Acrivon Therapeutics Inc (NASDAQ: ACRV) Trading Performance Indicators
Here are Acrivon Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 11.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.22, a number that is poised to hit -0.57 in the next quarter and is forecasted to reach -2.34 in one year’s time.
Technical Analysis of Acrivon Therapeutics Inc (ACRV)
Looking closely at Acrivon Therapeutics Inc (NASDAQ: ACRV), its last 5-days average volume was 0.87 million, which is a jump from its year-to-date volume of 0.42 million. As of the previous 9 days, the stock’s Stochastic %D was 10.21%. Additionally, its Average True Range was 0.20.
During the past 100 days, Acrivon Therapeutics Inc’s (ACRV) raw stochastic average was set at 0.87%, which indicates a significant decrease from 13.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.65% in the past 14 days, which was lower than the 162.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.5894, while its 200-day Moving Average is $5.9273. However, in the short run, Acrivon Therapeutics Inc’s stock first resistance to watch stands at $1.2550. Second resistance stands at $1.3600. The third major resistance level sits at $1.4300. If the price goes on to break the first support level at $1.0800, it is likely to go to the next support level at $1.0100. Now, if the price goes above the second support level, the third support stands at $0.9050.
Acrivon Therapeutics Inc (NASDAQ: ACRV) Key Stats
With a market capitalization of 36.06 million, the company has a total of 31,355K Shares Outstanding. Currently, annual sales are 0 K while annual income is -80,560 K. The company’s previous quarter sales were 0 K while its latest quarter income was -22,830 K.
